Virginia Laspidea
Pamplona, NC, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
High-Risk Rhabdomyosarcomas Feature a Convergent Cell State.
Journal: Cancer research
Published: September 26, 2025
Targeting the CD40 costimulatory receptor to improve virotherapy efficacy in diffuse midline gliomas.
Journal: Cell reports. Medicine
Published: October 08, 2024
The emerging field of viroimmunotherapy for pediatric brain tumors.
Journal: Neuro-oncology
Published: August 16, 2024
The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models.
Journal: Neuro-oncology
Published: March 30, 2024
Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma.
Journal: The New England journal of medicine
Published: June 29, 2022
Galectin-3 inhibition boosts the therapeutic efficacy of Semliki Forest virus in pediatric osteosarcoma.
Journal: Molecular therapy oncolytics
Published: April 04, 2022
Local Treatment of a Pediatric Osteosarcoma Model with a 4-1BBL Armed Oncolytic Adenovirus Results in an Antitumor Effect and Leads to Immune Memory.
Journal: Molecular cancer therapeutics
Published: June 29, 2021
CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models.
Journal: Journal for immunotherapy of cancer
Published: June 16, 2021
Delta-24-RGD, an Oncolytic Adenovirus, Increases Survival and Promotes Proinflammatory Immune Landscape Remodeling in Models of AT/RT and CNS-PNET.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 26, 2020
Last Updated: 09/26/2026